Thrombotic Disorders

  • Nahal LalefarEmail author
  • Robert Raphael
Part of the Pediatric Oncology book series (PEDIATRICO)


Thromboembolism is a well-recognized complication of cancer in children, with important clinical and therapeutic implications. The exact incidence is unknown, with wide variation in reported rates. Thromboembolism has been most extensively studied in acute lymphoblastic leukemia but also affects children with other malignancies. Risk factors include the presence or dysfunction of a central venous catheter, inherited thrombophilia, use of asparaginase and steroids, older age, and intrathoracic or metastatic disease. The most commonly affected sites are the central nervous system in acute lymphoblastic leukemia and the upper extremity veins which are often associated with a central venous catheter. Current evidence does not support screening asymptomatic patients or providing routine prophylactic anticoagulation in pediatric cancer patients. For patients with symptomatic thromboembolism, a review of the evidence for different therapeutic anticoagulation modalities is discussed with graded recommendations; due to a lack of reported data, much of the guidelines are based on expert opinion or consensus statements. The necessary duration of therapy is unknown but generally depends on clinical response and the presence of ongoing risk factors for bleeding or thrombosis. Additional research is needed to better understand the epidemiology of thrombosis in childhood cancer and to optimize both therapy and prevention.


Acute Lymphoblastic Leukemia National Comprehensive Cancer Network Superior Vena Cava Central Nervous System Event Dana Farber Cancer Institute 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Astwood E, Vora A (2011) Personal practice: how we manage the risk of bleeding and thrombosis in children and young adults with acute lymphoblastic leukaemia. Br J Haematol 152:505–511CrossRefPubMedGoogle Scholar
  2. Athale UH, Chan AK (2003a) Thrombosis in children with acute lymphoblastic leukemia: part I. Epidemiology of thrombosis in children with acute lymphoblastic leukemia. Thromb Res 111:125–131CrossRefPubMedGoogle Scholar
  3. Athale UH, Chan AK (2003b) Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy. Thromb Res 111:199–212Google Scholar
  4. Athale UH, Siciliano SA, Crowther M et al (2005) Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease. Br J Haematol 129:803–810CrossRefPubMedGoogle Scholar
  5. Athale U, Cox S, Siciliano S, Chan AK (2007) Thromboembolism in children with sarcoma. Pediatr Blood Cancer 49:171–176CrossRefPubMedGoogle Scholar
  6. Athale UH, Nagel K, Khan AA, Chan AK (2008a) Thromboembolism in children with lymphoma. Thromb Res 122:459–465CrossRefPubMedGoogle Scholar
  7. Athale U, Siciliano S, Thabane L et al (2008b) Epidemiology and clinical risk factors predisposing to thromboembolism in children with cancer. Pediatr Blood Cancer 51:792–797CrossRefPubMedGoogle Scholar
  8. Boulet SL, Amenda D, Gross SC, Hooper WC (2011) Health care expenditures associated with venous thromboembolism among children. Thromb Res 129:583–587CrossRefPubMedGoogle Scholar
  9. Caruso V, Iacoviello L, Di Castelnuovo A et al (2006) Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 108:2216–2222CrossRefPubMedGoogle Scholar
  10. Deitcher SR, Gajjar A, Kun L, Heideman RL (2004) Clinically evident venous thromboembolic events in children with brain tumors. J Pediatr 145:848–850CrossRefPubMedGoogle Scholar
  11. Dipasco PJ, Misra S, Koniaris LG, Moffat FL Jr (2011) Thrombophilic state in cancer, part I: biology, incidence, and risk factors. J Surg Oncol 104:316–322CrossRefPubMedGoogle Scholar
  12. Dipasco PJ, Misra S, Koniaris LG, Moffat FL Jr (2012) The thrombophilic state in cancer part II: cancer outcomes, occult malignancy, and cancer suppression. J Surg Oncol 106:517–523CrossRefPubMedGoogle Scholar
  13. Elhasid R, Lanir N, Sharon R et al (2001) Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis 12:367–370CrossRefPubMedGoogle Scholar
  14. Glaser DW, Medeiros D, Rollins N, Buchanan GR (2001) Catheter-related thrombosis in children with cancer. J Pediatr 138:255–259CrossRefPubMedGoogle Scholar
  15. Grace RF, Dahlberg SE, Neuberg D et al (2011) The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol 152:452–459Google Scholar
  16. Guyatt G, Gutterman D, Baumann MH et al (2006) Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians Task Force. Chest 129:174–181CrossRefPubMedGoogle Scholar
  17. Harlev D, Zaidman I, Sarig G et al (2010) Prophylactic therapy with enoxaparin in children with acute lymphoblastic leukemia and inherited thrombophilia during L-asparaginase treatment. Thromb Res 126:93–97CrossRefPubMedGoogle Scholar
  18. Kerlin BA (2012) Current and future management of pediatric venous thromboembolism. Am J Hematol 87:S68–S74CrossRefPubMedCentralPubMedGoogle Scholar
  19. Khorana AA, Streiff MB, Farge D et al (2009) Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol 27:4919–4926CrossRefPubMedCentralPubMedGoogle Scholar
  20. Kuhle S, Spavor M, Massicotte P et al (2008) Prevalence of post-thrombotic syndrome following asymptomatic thrombosis in survivors of acute lymphoblastic leukemia. J Thromb Haemost 6:589–594CrossRefPubMedGoogle Scholar
  21. Male C, Chait P, Andrew M et al (2003) Central venous line-related thrombosis in children: association with central venous line location and insertion technique. Blood 101:4273–4278CrossRefPubMedGoogle Scholar
  22. Manco-Johnson MJ (2006) How I treat venous thrombosis in children. Blood 107:21–29CrossRefPubMedCentralPubMedGoogle Scholar
  23. Massicotte P, Julian JA, Gent M et al (2003) An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thromb Res 109:101–108CrossRefPubMedGoogle Scholar
  24. McLean TW, Fisher CJ, Snively BM, Chauvenet AR (2005) Central venous lines in children with lesser risk acute lymphoblastic leukemia: optimal type and timing of placement. J Clin Oncol 23:3024–3029CrossRefPubMedGoogle Scholar
  25. Meister B, Kropshofer G, Klein-Franke A et al (2008) Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 50:298–303CrossRefPubMedGoogle Scholar
  26. Mitchell L, Andrew M, Hanna K et al (2003a) Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost 90:235–244PubMedGoogle Scholar
  27. Mitchell LG, Andrew M, Hanna K et al (2003b) A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer 97:508–516CrossRefPubMedGoogle Scholar
  28. Mitchell L, Lambers M, Flege S et al (2010) Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study. Blood 115:4999–5004CrossRefPubMedCentralPubMedGoogle Scholar
  29. Monagle P, Chan AK, Goldenberg NA et al (2012) Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e737S–e801SCrossRefPubMedCentralPubMedGoogle Scholar
  30. Nowak-Göttl U, Wermes C, Junker R et al (1999) Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood 93:1595–1599PubMedGoogle Scholar
  31. Nowak-Göttl U, Heinecke A, von Kries R et al (2001) Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration. Thromb Res 103:165–172CrossRefPubMedGoogle Scholar
  32. Nowak-Göttl U, Ahlke E, Fleischhack G et al (2003) Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration. Blood 101:2529–2533CrossRefPubMedGoogle Scholar
  33. Nowak-Göttl U, Kenet G, Mitchell LG (2009) Thrombosis in childhood acute lymphoblastic leukaemia: epidemiology, aetiology, diagnosis, prevention and treatment. Best Pract Res Clin Haematol 22:103–114CrossRefPubMedGoogle Scholar
  34. Payne JH, Vora AJ (2007) Thrombosis and acute lymphoblastic leukaemia. Br J Haematol 138:430–445CrossRefPubMedGoogle Scholar
  35. Paz-Priel I, Long L, Helman LJ et al (2007) Thromboembolic events in children and young adults with pediatric sarcoma. J Clin Oncol 25:1519–1524CrossRefPubMedGoogle Scholar
  36. Qureshi A, Mitchell C, Richards S et al (2010) Asparaginase-related venous thrombosis in UKALL 2003—re-exposure to asparaginase is feasible and safe. Br J Haematol 149:410–413CrossRefPubMedGoogle Scholar
  37. Raffini L, Thornburg C (2009) Testing children for inherited thrombophilia: more questions than answers. Br J Haematol 147:277–288Google Scholar
  38. Ruud E, Holmstrøm H, De Lange C et al (2006) Low-dose warfarin for the prevention of central line-associated thromboses in children with malignancies—a randomized, controlled study. Acta Paediatr 95:1053–1059CrossRefPubMedGoogle Scholar
  39. Silverman LB, Gelber RD, Dalton VK et al (2001) Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 97:1211–1218Google Scholar
  40. Silverman LB, Supko JG, Stevenson KE et al (2010) Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood 115:1351–1353CrossRefPubMedCentralPubMedGoogle Scholar
  41. Tabori U, Beni-Adani L, Dvir R et al (2004) Risk of venous thromboembolism in pediatric patients with brain tumors. Pediatr Blood Cancer 43:633–636CrossRefPubMedGoogle Scholar
  42. Wiernikowski JT, Athale UH (2006) Thromboembolic complications in children with cancer. Thromb Res 118:137–152CrossRefPubMedGoogle Scholar

Copyright information

© Springer Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of Hematology/OncologyChildren’s Hospital and Research Center OaklandOaklandUSA

Personalised recommendations